» Articles » PMID: 30941097

The Electrophysiology of Presynaptic Congenital Myasthenic Syndromes With and Without Facilitation: From Electrodiagnostic Findings to Molecular Mechanisms

Overview
Journal Front Neurol
Specialty Neurology
Date 2019 Apr 4
PMID 30941097
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital myasthenic syndromes (CMS) are a group of inherited disorders of neuromuscular transmission most commonly presenting with early onset fatigable weakness, ptosis, and ophthalmoparesis. CMS are classified according to the localization of the causative molecular defect. CMS with presynaptic dysfunction can be caused by mutations in several different genes, including those involved in acetylcholine synthesis, its packaging into synaptic vesicles, vesicle docking, and release from the presynaptic nerve terminal and neuromuscular junction development and maintenance. Electrodiagnostic testing is key in distinguishing CMS from other neuromuscular disorders with similar clinical features as well as for revealing features pointing to a specific molecular diagnosis. A decremental response on low-frequency repetitive nerve stimulation (RNS) is present in most presynaptic CMS. In CMS with deficits in acetylcholine resynthesis however, a decrement may only appear after conditioning with exercise or high-frequency RNS and characteristically displays a slow recovery. Facilitation occurs in CMS caused by mutations in . By contrast, facilitation is absent in the other presynaptic CMS described to date. An understanding of the underlying molecular mechanisms therefore assists the interpretation of electrodiagnostic findings in patients with suspected CMS.

Citing Articles

A Common Gene Mutation of Congenital Myasthenic Syndrome Found in Kadazandusun Children.

Tan K, Chew H, Yacob Y, Khoo T J Pediatr Genet. 2024; 13(3):232-236.

PMID: 39086444 PMC: 11288710. DOI: 10.1055/s-0042-1750747.


Congenital myasthenic syndromes: increasingly complex.

Ramdas S, Beeson D, Dong Y Curr Opin Neurol. 2024; 37(5):493-501.

PMID: 39051439 PMC: 11377046. DOI: 10.1097/WCO.0000000000001300.


Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.

Ohno K, Ohkawara B, Shen X, Selcen D, Engel A Int J Mol Sci. 2023; 24(4).

PMID: 36835142 PMC: 9961056. DOI: 10.3390/ijms24043730.


Phenotypical and Myopathological Consequences of Compound Heterozygous Missense and Nonsense Variants in .

Marina A, Arlt A, Schara-Schmidt U, Depienne C, Gangfuss A, Kolbel H Cells. 2021; 10(12).

PMID: 34943989 PMC: 8700530. DOI: 10.3390/cells10123481.


The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies.

Vanhaesebrouck A, Beeson D Curr Opin Neurol. 2019; 32(5):696-703.

PMID: 31361628 PMC: 6735524. DOI: 10.1097/WCO.0000000000000736.

References
1.
Ohno K, Tsujino A, Brengman J, Harper C, Bajzer Z, Udd B . Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A. 2001; 98(4):2017-22. PMC: 29374. DOI: 10.1073/pnas.98.4.2017. View

2.
Byring R, Pihko H, Tsujino A, Shen X, Gustafsson B, Hackman P . Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. Neuromuscul Disord. 2002; 12(6):548-53. DOI: 10.1016/s0960-8966(01)00336-4. View

3.
Engel A, Ohno K, Sine S . Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nat Rev Neurosci. 2003; 4(5):339-52. DOI: 10.1038/nrn1101. View

4.
Sorensen J, Nagy G, Varoqueaux F, Nehring R, Brose N, Wilson M . Differential control of the releasable vesicle pools by SNAP-25 splice variants and SNAP-23. Cell. 2003; 114(1):75-86. DOI: 10.1016/s0092-8674(03)00477-x. View

5.
Ferguson S, Bazalakova M, Savchenko V, Tapia J, Wright J, Blakely R . Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. Proc Natl Acad Sci U S A. 2004; 101(23):8762-7. PMC: 423269. DOI: 10.1073/pnas.0401667101. View